{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:40:31Z","timestamp":1787838031358,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Human respiratory syncytial virus (hRSV) is a highly contagious pathogen and is the most common cause of bronchiolitis and pneumonia for infants and children under one year of age. Worldwide, greater than 33 million children under five years of age are affected by hRSV resulting in three million hospitalizations and 200,000 deaths. However, severe lower respiratory tract disease may occur at any age, especially among the elderly or those with compromised cardiac, pulmonary, or immune systems. There is no vaccine commercially available. Existing therapies for the acute infection are ribavirin and the prophylactic humanized monoclonal antibody (Synagis\u00ae from MedImmune) that is limited to use in high risk pediatric patients. Thus, the discovery of new inhibitors for hRSV would be clinically beneficial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We have developed and validated a 384-well cell-based, high-throughput assay that measures the cytopathic effect of hRSV (strain Long) in HEp-2 cells using a luminescent-based detection system for signal endpoint (Cell Titer Glo\u00ae). The assay is sensitive and robust, with Z factors greater than 0.8, signal to background greater than 35, and signal to noise greater than 24. Utilizing this assay, 313,816 compounds from the Molecular Libraries Small Molecule Repository were screened at 10 \u03bcM. We identified 7,583 compounds that showed greater than 22% CPE inhibition in the primary screen. The top 2,500 compounds were selected for confirmation screening and 409 compounds showed at least 50% inhibition of CPE and were considered active. We selected fifty-one compounds, based on potency, selectivity and chemical tractability, for further evaluation in dose response and secondary assays Several compounds had SI<jats:sub>50<\/jats:sub> values greater than 3, while the most active compound displayed an SI<jats:sub>50<\/jats:sub> value of 58.9.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A robust automated luminescent-based high throughput screen that measures the inhibition of hRSV-induced cytopathic effect in HEp-2 cells for the rapid identification of potential inhibitors from large compound libraries has been developed, optimized and validated. The active compounds identified in the screen represent different classes of molecules, including aryl sulfonylpyrrolidines which have not been previously identified as having anti-hRSV activity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1743-422x-10-19","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T03:36:28Z","timestamp":1357788988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus"],"prefix":"10.1186","volume":"10","author":[{"given":"Dong-Hoon","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake P","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daljit S","family":"Matharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Maddox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda I","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramaniam","family":"Ananthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Lucile","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuli","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen B","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E","family":"Severson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,10]]},"reference":[{"issue":"3","key":"2098_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/00063198-200205000-00011","volume":"8","author":"A Greenough","year":"2002","unstructured":"Greenough A: Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr Opin Pulm Med 2002,8(3):214-217. 10.1097\/00063198-200205000-00011","journal-title":"Curr Opin Pulm Med"},{"issue":"Suppl 1","key":"2098_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1086\/591851","volume":"48","author":"F Hayden","year":"2009","unstructured":"Hayden F: Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009,48(Suppl 1):S3-S13.","journal-title":"Clin Infect Dis"},{"issue":"3A","key":"2098_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0002-9343(97)00014-4","volume":"102","author":"JA Englund","year":"1997","unstructured":"Englund JA, Piedra PA, Whimbey E: Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med 1997,102(3A):61-70. discussion 75-6","journal-title":"Am J Med"},{"issue":"5","key":"2098_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00019053-200422050-00001","volume":"22","author":"LC Paramore","year":"2004","unstructured":"Paramore LC, et al.: Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. PharmacoEconomics 2004,22(5):275-284. 10.2165\/00019053-200422050-00001","journal-title":"PharmacoEconomics"},{"issue":"21","key":"2098_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399406000081","volume":"8","author":"RJ Sugrue","year":"2006","unstructured":"Sugrue RJ: Interactions between respiratory syncytial virus and the host cell: opportunities for antivirus strategies? Expert Rev Mol Med 2006,8(21):1-17.","journal-title":"Expert Rev Mol Med"},{"issue":"15","key":"2098_CR6","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1128\/JVI.75.15.6825-6834.2001","volume":"75","author":"S Techaarpornkul","year":"2001","unstructured":"Techaarpornkul S, Barretto N, Peeples ME: Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and\/or attachment glycoprotein gene. J Virol 2001,75(15):6825-6834. 10.1128\/JVI.75.15.6825-6834.2001","journal-title":"J Virol"},{"issue":"2","key":"2098_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1006\/viro.2001.1138","volume":"289","author":"MN Teng","year":"2001","unstructured":"Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001,289(2):283-296. 10.1006\/viro.2001.1138","journal-title":"Virology"},{"issue":"13","key":"2098_CR8","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1016\/j.febslet.2010.05.006","volume":"584","author":"SD Carter","year":"2010","unstructured":"Carter SD, et al.: Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability. FEBS Lett 2010,584(13):2786-2790. 10.1016\/j.febslet.2010.05.006","journal-title":"FEBS Lett"},{"issue":"29","key":"2098_CR9","doi-asserted-by":"publisher","first-page":"24671","DOI":"10.1074\/jbc.M111.332791","volume":"287","author":"SW Gan","year":"2012","unstructured":"Gan SW, et al.: The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. J Biol Chem 2012,287(29):24671-24689. 10.1074\/jbc.M111.332791","journal-title":"J Biol Chem"},{"issue":"1","key":"2098_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1073\/pnas.93.1.81","volume":"93","author":"PL Collins","year":"1996","unstructured":"Collins PL, et al.: Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc Natl Acad Sci U S A 1996,93(1):81-85. 10.1073\/pnas.93.1.81","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2098_CR11","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1128\/JVI.73.7.5852-5864.1999","volume":"73","author":"R Fearns","year":"1999","unstructured":"Fearns R, Collins PL: Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol 1999,73(7):5852-5864.","journal-title":"J Virol"},{"issue":"1","key":"2098_CR12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1128\/JVI.72.1.520-526.1998","volume":"72","author":"RW Hardy","year":"1998","unstructured":"Hardy RW, Wertz GW: The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol 1998,72(1):520-526.","journal-title":"J Virol"},{"issue":"4","key":"2098_CR13","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1128\/jvi.69.4.2412-2419.1995","volume":"69","author":"Q Yu","year":"1995","unstructured":"Yu Q, Hardy RW, Wertz GW: Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication. J Virol 1995,69(4):2412-2419.","journal-title":"J Virol"},{"issue":"2","key":"2098_CR14","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1128\/JVI.72.2.1452-1461.1998","volume":"72","author":"PL Atreya","year":"1998","unstructured":"Atreya PL, Peeples ME, Collins PL: The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication. J Virol 1998,72(2):1452-1461.","journal-title":"J Virol"},{"issue":"20","key":"2098_CR15","doi-asserted-by":"publisher","first-page":"11259","DOI":"10.1073\/pnas.96.20.11259","volume":"96","author":"A Bermingham","year":"1999","unstructured":"Bermingham A, Collins PL: The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A 1999,96(20):11259-11264. 10.1073\/pnas.96.20.11259","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2098_CR16","first-page":"311","volume":"7615","author":"TN Jeffcoate","year":"1969","unstructured":"Jeffcoate TN: Vaccine against respiratory syncytial virus. Lancet 1969,7615(2):311.","journal-title":"Lancet"},{"key":"2098_CR17","first-page":"7","volume-title":"Respiratory syncytial virus: a brief history, in Contemporary diagnosis and management of respiratory syncytial virus. Handbooks in Health Care Co","author":"VG Hemming","year":"2000","unstructured":"Hemming VG: Respiratory syncytial virus: a brief history, in Contemporary diagnosis and management of respiratory syncytial virus. Handbooks in Health Care Co. Edited by: Weisman LE, Groothuis JR. Newtown: PA; 2000:7-23."},{"issue":"24","key":"2098_CR18","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJM198306163082403","volume":"308","author":"CB Hall","year":"1983","unstructured":"Hall CB, et al.: Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. a randomized double-blind study. N Engl J Med 1983,308(24):1443-1447. 10.1056\/NEJM198306163082403","journal-title":"N Engl J Med"},{"issue":"2","key":"2098_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00006454-198702000-00004","volume":"6","author":"WJ Rodriguez","year":"1987","unstructured":"Rodriguez WJ, et al.: Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J 1987,6(2):159-163. 10.1097\/00006454-198702000-00004","journal-title":"Pediatr Infect Dis J"},{"key":"2098_CR20","unstructured":"Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants Paediatr Child Health 1999,4(7):474-489."},{"issue":"3","key":"2098_CR21","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1128\/JVI.79.3.1943-1947.2005","volume":"79","author":"P Leyssen","year":"2005","unstructured":"Leyssen P, et al.: The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005,79(3):1943-1947. 10.1128\/JVI.79.3.1943-1947.2005","journal-title":"J Virol"},{"issue":"10","key":"2098_CR22","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1128\/AAC.33.10.1668","volume":"33","author":"R Fernandez-Larsson","year":"1989","unstructured":"Fernandez-Larsson R, et al.: Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicrob Agents Chemother 1989,33(10):1668-1673. 10.1128\/AAC.33.10.1668","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2098_CR23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1128\/AAC.11.6.946","volume":"11","author":"B Eriksson","year":"1977","unstructured":"Eriksson B, et al.: Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977,11(6):946-951. 10.1128\/AAC.11.6.946","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2098_CR24","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1021\/jm051185t","volume":"49","author":"MC Carter","year":"2006","unstructured":"Carter MC, et al.: 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. J Med Chem 2006,49(7):2311-2319. 10.1021\/jm051185t","journal-title":"J Med Chem"},{"issue":"3","key":"2098_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1006\/meth.1998.0628","volume":"15","author":"MR Player","year":"1998","unstructured":"Player MR, et al.: Ribonuclease L, a 2-5A-dependent enzyme: purification to homogeneity and assays for 2-5A binding and catalytic activity. Methods 1998,15(3):243-253. 10.1006\/meth.1998.0628","journal-title":"Methods"},{"issue":"1\u20132","key":"2098_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0166-0934(92)90125-W","volume":"39","author":"KL Rubino","year":"1992","unstructured":"Rubino KL, Nicholas JA: A novel, spectrophotometric microneutralization assay for respiratory syncytial virus. J Virol Methods 1992,39(1\u20132):55-67.","journal-title":"J Virol Methods"},{"issue":"4","key":"2098_CR27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","volume":"44","author":"W Markland","year":"2000","unstructured":"Markland W, et al.: Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 2000,44(4):859-866. 10.1128\/AAC.44.4.859-866.2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"17","key":"2098_CR28","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1021\/jm00095a020","volume":"35","author":"B Gabrielsen","year":"1992","unstructured":"Gabrielsen B, et al.: Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride. J Med Chem 1992,35(17):3231-3238. 10.1021\/jm00095a020","journal-title":"J Med Chem"},{"issue":"3","key":"2098_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.antiviral.2003.07.004","volume":"60","author":"K Andries","year":"2003","unstructured":"Andries K, et al.: Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res 2003,60(3):209-219. 10.1016\/j.antiviral.2003.07.004","journal-title":"Antiviral Res"},{"issue":"2","key":"2098_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1128\/AAC.48.2.413-422.2004","volume":"48","author":"C Cianci","year":"2004","unstructured":"Cianci C, et al.: Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 2004,48(2):413-422. 10.1128\/AAC.48.2.413-422.2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2098_CR31","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1128\/JVI.77.9.5054-5064.2003","volume":"77","author":"JL Douglas","year":"2003","unstructured":"Douglas JL, et al.: Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol 2003,77(9):5054-5064. 10.1128\/JVI.77.9.5054-5064.2003","journal-title":"J Virol"},{"issue":"7","key":"2098_CR32","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1074-5521(01)00042-4","volume":"8","author":"V Razinkov","year":"2001","unstructured":"Razinkov V, et al.: RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol 2001,8(7):645-659. 10.1016\/S1074-5521(01)00042-4","journal-title":"Chem Biol"},{"issue":"2","key":"2098_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.antiviral.2004.12.002","volume":"65","author":"K Sudo","year":"2005","unstructured":"Sudo K, et al.: YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 2005,65(2):125-131. 10.1016\/j.antiviral.2004.12.002","journal-title":"Antiviral Res"},{"issue":"20","key":"2098_CR34","doi-asserted-by":"publisher","first-page":"13105","DOI":"10.1128\/JVI.79.20.13105-13115.2005","volume":"79","author":"M Liuzzi","year":"2005","unstructured":"Liuzzi M, et al.: Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol 2005,79(20):13105-13115. 10.1128\/JVI.79.20.13105-13115.2005","journal-title":"J Virol"},{"issue":"4","key":"2098_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1586\/14787210.2.4.625","volume":"2","author":"JL Douglas","year":"2004","unstructured":"Douglas JL: In search of a small-molecule inhibitor for respiratory syncytial virus. Expert Rev Anti Infect Ther 2004,2(4):625-639. 10.1586\/14787210.2.4.625","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"2098_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.antiviral.2003.09.008","volume":"61","author":"K Kimura","year":"2004","unstructured":"Kimura K, et al.: Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus. Antiviral Res 2004,61(3):165-171. 10.1016\/j.antiviral.2003.09.008","journal-title":"Antiviral Res"},{"key":"2098_CR37","unstructured":"Informa UK Ltd. Pharmaprojects Pharmaceutical Research & Development Pipeline Intelligence. 2008."},{"issue":"17","key":"2098_CR38","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1073\/pnas.1017142108","volume":"108","author":"A Bonavia","year":"2011","unstructured":"Bonavia A, et al.: Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci U S A 2011,108(17):6739-6744. 10.1073\/pnas.1017142108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2098_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang JH, Chung TD, Oldenburg KR: A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 1999,4(2):67-73. 10.1177\/108705719900400206","journal-title":"J Biomol Screen"},{"issue":"1","key":"2098_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.antiviral.2005.06.003","volume":"68","author":"RW Sidwell","year":"2005","unstructured":"Sidwell RW, et al.: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005,68(1):10-17. 10.1016\/j.antiviral.2005.06.003","journal-title":"Antiviral Res"},{"issue":"3","key":"2098_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.antiviral.2003.07.002","volume":"60","author":"PR Wyde","year":"2003","unstructured":"Wyde PR, et al.: Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res 2003,60(3):221-231. 10.1016\/j.antiviral.2003.07.002","journal-title":"Antiviral Res"},{"issue":"2","key":"2098_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1089\/adt.2010.0298","volume":"9","author":"L Rasmussen","year":"2011","unstructured":"Rasmussen L, et al.: A High-Throughput Screening Strategy to Overcome Virus Instability. Assay Drug Dev Technol 2011,9(2):184-190. 10.1089\/adt.2010.0298","journal-title":"Assay Drug Dev Technol"},{"key":"2098_CR43","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed LJ, Muench H: A simple method of estimating fifty percent endpoints. Am J Hygiene 1938, 27: 493-497.","journal-title":"Am J Hygiene"},{"issue":"20","key":"2098_CR44","doi-asserted-by":"publisher","first-page":"8582","DOI":"10.1021\/jm300612z","volume":"55","author":"BP Moore","year":"2012","unstructured":"Moore BP, et al.: (S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a Small Molecule Inhibitor Probe for the Study of Respiratory Syncytial Virus Infection. J Med Chem 2012,55(20):8582-8587. 10.1021\/jm300612z","journal-title":"J Med Chem"},{"issue":"5","key":"2098_CR45","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1086\/423213","volume":"190","author":"JP DeVincenzo","year":"2004","unstructured":"DeVincenzo JP, et al.: Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 2004,190(5):975-978. 10.1086\/423213","journal-title":"J Infect Dis"},{"issue":"2","key":"2098_CR46","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.virol.2003.10.018","volume":"318","author":"X Zhao","year":"2004","unstructured":"Zhao X, Chen FP, Sullender WM: Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 2004,318(2):608-612. 10.1016\/j.virol.2003.10.018","journal-title":"Virology"},{"issue":"7","key":"2098_CR47","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1128\/JVI.79.7.3962-3968.2005","volume":"79","author":"X Zhao","year":"2005","unstructured":"Zhao X, Sullender WM: In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 2005,79(7):3962-3968. 10.1128\/JVI.79.7.3962-3968.2005","journal-title":"J Virol"},{"issue":"2","key":"2098_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1086\/653534","volume":"51","author":"O Adams","year":"2010","unstructured":"Adams O, et al.: Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis 2010,51(2):185-188. 10.1086\/653534","journal-title":"Clin Infect Dis"},{"issue":"15","key":"2098_CR49","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0264-410X(96)00096-5","volume":"14","author":"CK Gupta","year":"1996","unstructured":"Gupta CK, et al.: Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 1996,14(15):1417-1420. 10.1016\/S0264-410X(96)00096-5","journal-title":"Vaccine"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-10-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:57:33Z","timestamp":1630537053000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-10-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2098"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-10-19","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,10]]},"assertion":[{"value":"6 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"19"}}